Related stories
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
How not to revive Europe’s auto industry
White House asks US envoy to Greece Kimberly Guilfoyle to resign
Why one hedge-fund billionaire believes stocks are heading for a ‘really challenging’ 2027
This one move will save $20,000 on our wedding
Micron’s stock extends declines as China competition heats up